SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Gurpreet Kaur Randhawa, Navyug Raj Singh, Jaswant Rai, Gobindnoor Kaur, Resham Kashyap, A Critical Analysis of Claims and Their Authenticity in Indian Drug Promotional Advertisements, Advances in Medicine, 2015, 2015, 1

    CrossRef

  2. 2
    Adolfo Díez-Pérez, Jonathan D Adachi, Silvano Adami, Frederick A Anderson, Steven Boonen, Roland Chapurlat, Juliet E Compston, Cyrus Cooper, Stephen H Gehlbach, Susan L Greenspan, Frederick H Hooven, Andrea Z LaCroix, Jeri W Nieves, J Coen Netelenbos, Johannes Pfeilschifter, Maurizio Rossini, Christian Roux, Kenneth G Saag, Stuart Silverman, Ethel S Siris, Allison Wyman, Sophie K Rushton-Smith, Nelson B Watts, Risk Factors for Treatment Failure With Antiosteoporosis Medication: The Global Longitudinal Study of Osteoporosis in Women (GLOW), Journal of Bone and Mineral Research, 2014, 29, 1
  3. 3
    Charles A. Inderjeeth, Kien Chan, Kevin Kwan, Michelle Lai, Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments, Journal of Bone and Mineral Metabolism, 2012, 30, 5, 493

    CrossRef

  4. 4
    A. Diez-Perez, J. D. Adachi, D. Agnusdei, J. P. Bilezikian, J. E. Compston, S. R. Cummings, R. Eastell, E. F. Eriksen, J. Gonzalez-Macias, U. A. Liberman, D. A. Wahl, E. Seeman, J. A. Kanis, C. Cooper, Treatment failure in osteoporosis, Osteoporosis International, 2012, 23, 12, 2769

    CrossRef

  5. 5
    G. C. Isaia, V. Braga, S. Minisola, G. Bianchi, A. Del Puente, L. Di Matteo, G. Pagano Mariano, V. M. Latte, F. D’Amico, C. Bonali, P. D’Amelio, Clinical characteristics and incidence of first fracture in a consecutive sample of post-menopausal women attending osteoporosis centers: The PROTEO-1 study, Journal of Endocrinological Investigation, 2011, 34, 7, 534

    CrossRef

  6. 6
    Z. Sanad, H. Ellakwa, B. Desouky, Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis, Climacteric, 2011, 14, 3, 369

    CrossRef

  7. 7
    S. Ojeda-Bruno, A. Naranjo, F. Francisco-Hernández, C. Erausquin, I. Rúa-Figueroa, J. C. Quevedo, C. Rodríguez-Lozano, Secondary prevention program for osteoporotic fractures and long-term adherence to bisphosphonates, Osteoporosis International, 2011, 22, 6, 1821

    CrossRef

  8. 8
    D. M. Reid, D. Hosking, D. Kendler, M. L. Brandi, J. D. Wark, J. F. Marques-Neto, G. Weryha, N. Verbruggen, C. M. Hustad, E. M. Mahlis, M. E. Melton, A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International, International Journal of Clinical Practice, 2008, 62, 4
  9. 9
    Earl R Bogoch, Victoria Elliot-Gibson, Benjamin G Escott, Dorcas E Beaton, The Osteoporosis Needs of Patients With Wrist Fracture, Journal of Orthopaedic Trauma, 2008, 22, S73

    CrossRef

  10. 10
    O. Gajic-Veljanoski, R. J. Sebaldt, A. M. Davis, D. Tritchler, G. Tomlinson, A. Petrie, J. D. Adachi, A. M. Cheung, Age and drug therapy are key prognostic factors for first clinical fracture in patients with primary osteoporosis, Osteoporosis International, 2007, 18, 8, 1091

    CrossRef

  11. 11
    M. Schwenkglenks, K. Lippuner, Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland, Osteoporosis International, 2007, 18, 11, 1481

    CrossRef

  12. 12
    P J J Prinsloo, D J Hosking, Alendronate sodium in the management of osteoporosis, Therapeutics and Clinical Risk Management, 2006, 2, 3, 235

    CrossRef

  13. 13
    David M Reid, David Hosking, David Kendler, Maria L Brandi, John D Wark, Georges Weryha, Jo??o F Marques-Neto, Keavy A Gaines, Nadia Verbruggen, Mary E Melton, Alendronic Acid Produces Greater Effects than Risedronic Acid on Bone??Density and Turnover in Postmenopausal Women with Osteoporosis, Clinical Drug Investigation, 2006, 26, 2, 63

    CrossRef

  14. 14
    Mengu Sarioglu, Cigdem Tuzun, Zeliha Unlu, Canan Tikiz, Fatma Taneli, B. Sami. Uyanik, Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis, Rheumatology International, 2006, 26, 3, 195

    CrossRef

  15. 15
    Rachael L. Fleurence, Cynthia P. Iglesias, David J. Torgerson, Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature, Osteoporosis International, 2006, 17, 1, 29

    CrossRef

  16. 16
    David C. McCarus, Fracture Prevention in Postmenopausal Osteoporosis: A Review of Treatment Options, Obstetrical & Gynecological Survey, 2006, 61, 1, 39

    CrossRef

  17. 17
    Uri A Liberman, Long-Term Safety of Bisphosphonate Therapy for Osteoporosis, Drugs & Aging, 2006, 23, 4, 289

    CrossRef

  18. 18
    Ronald C. Hamdy, Charles H. Chesnut, Margery L. Gass, Michael F. Holick, Edward S. Leib, Michael E. Lewiecki, Michael Maricic, Nelson B. Watts, Review of Treatment Modalities for Postmenopausal Osteoporosis, Southern Medical Journal, 2005, 98, 10, 1000

    CrossRef

  19. 19
    Solomon Epstein, The Roles of Bone Mineral Density, Bone Turnover, and Other Properties in Reducing Fracture Risk During Antiresorptive Therapy, Mayo Clinic Proceedings, 2005, 80, 3, 379

    CrossRef

  20. 20
    P. N. Sambrook, P. Geusens, C. Ribot, J. A. Solimano, J. Ferrer-Barriendos, K. Gaines, N. Verbruggen, M. E. Melton, Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (EFficacy of FOSAMAX® versus EVISTA®Comparison Trial) International, Journal of Internal Medicine, 2004, 255, 4
  21. 21
    Marc C. Hochberg, Paul D. Miller, Richard D. Wasnich, Philip D. Ross, Susan Greenspan, Letter to the Editor, Bone, 2004, 35, 5, 1222

    CrossRef

  22. 22
    Marjorie Luckey, Risa Kagan, Susan Greenspan, Henry Bone, R. Douglas P. Kiel, James Simon, Jennifer Sackarowitz, Joanne Palmisano, Erluo Chen, Richard A. Petruschke, Anne E. de Papp, Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis*, Menopause, 2004, 11, 4, 405

    CrossRef

  23. 23
    Faustino R. Pérez-López, Postmenopausal osteoporosis and alendronate, Maturitas, 2004, 48, 3, 179

    CrossRef

  24. 24
    Ted Xenodemetropoulos, Shawn Davison, George Ioannidis, Jonathan D Adachi, The Impact of Fragility Fracture on Health-Related Quality of Life, Drugs & Aging, 2004, 21, 11, 711

    CrossRef

  25. 25
    Paul Miller, Analysis of 1-year Vertebral Fracture Risk Reduction Data in Treatments for Osteoporosis, Southern Medical Journal, 2003, 96, 5, 478

    CrossRef

  26. 26
    Ian R. Reid, Bisphosphonates: new indications and methods of administration, Current Opinion in Rheumatology, 2003, 15, 4, 458

    CrossRef

  27. 27
    David Hosking, Silvano Adami, Dieter Felsenberg, Jorge Cannata Andia, Matti Välimäki, Laurent Benhamou, Jean-Yves Reginster, Carol Yacik, Andrea Rybak-Feglin, Richard A. Petruschke, Luna Zaru, Arthur C. Santora, Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study, Current Medical Research and Opinion, 2003, 19, 5, 383

    CrossRef

  28. 28
    Margaret J. Gunter, Sarah J. Beaton, Susan K. Brenneman, Ya-Ting Chen, Thomas A. Abbott, Jeremy M. Gleeson, Management of Osteoporosis in Women Aged 50 and Older with Osteoporosis-Related Fractures in a Managed Care Population, Disease Management, 2003, 6, 2, 83

    CrossRef